Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Cost of RevenueDepreciation ExpenseEBIATGross ProfitReceivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Immuron (IMRN) Gross Profit (2016 - 2024)

Immuron's quarterly Gross Profit came in at -$1737594727.2 billion in Q4 2024, down 109950132958505.31% year-on-year from N/an in Q1 2024, and down 109950132958505.31% quarter-over-quarter from $1.6 million in Q4 2023.

Immuron has reported Gross Profit for 9 years, with the latest figure at -$1737594727.2 billion in Q4 2024.

  • For the quarter ending Q4 2024, Gross Profit fell 109950132958505.31% year-over-year to -$1737594727.2 billion; the trailing twelve-month figure through Dec 2024 stood at -$1737594727.2 billion (down 83615547705664.03% YoY), and the FY2025 full-year result was $3.1 million, up 41.12% from the prior year.
  • Gross Profit for Q4 2024 stood at -$1737594727.2 billion, down from $1.6 million in the prior quarter.
  • The five-year high for Gross Profit was $1.6 million in Q4 2023, with the low at -$1737594727.2 billion in Q4 2024.
  • Average Gross Profit over 5 years is -$289599121.2 billion, with a median of $37175.4 recorded in 2020.
  • Year-over-year, Gross Profit soared 36261.27% in 2022 and sank 109950132958505.31% in 2024.
  • Tracing IMRN's Gross Profit over 5 years: stood at $5719.6 in 2020, then slumped by 79.42% to $1176.9 in 2021, then soared by 36261.27% to $427920.0 in 2022, then soared by 269.31% to $1.6 million in 2023, then slumped by 109950132958505.31% to -$1737594727.2 billion in 2024.
  • The last three Gross Profit figures came in at -$1737594727.2 billion (Q4 2024), $1.6 million (Q4 2023), and $68631.3 (Q2 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn
7 Evaxion A 62.56 Bn 62.54 Bn -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn
10 Immuron 1.27 Bn 1.27 Bn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2024 -1,737,594,727.21 Bn
Dec 31, 2024 -1,737,594,727.21 Bn
Dec 31, 2023 1.58 Mn
Dec 31, 2023 1.58 Mn
Jun 30, 2023 68,631.26
Jun 30, 2023 68,631.26
Dec 31, 2022 427,920.00
Dec 31, 2022 427,920.00
Dec 31, 2021 1,176.86
Dec 31, 2021 1,176.86
Dec 31, 2020 5,719.56
Dec 31, 2020 5,719.56
Dec 31, 2019 11,214.25
Dec 31, 2019 11,214.25
Dec 31, 2018 746,754.00
Dec 31, 2018 746,754.00
Dec 31, 2017 564,074.12
Dec 31, 2017 564,074.12
Dec 31, 2016 361,687.03
Dec 31, 2016 361,687.03
Jun 30, 2016 637,749.57
Jun 30, 2016 637,749.57